Combined intravitreal therapy for age-related macular disease;Kombinierte intravitreale therapie zur behandlung der altersbedingten makuladegeneration

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 12, 2008, Pages 1003-1008

  Koch, Frank ^a,b   Scholtz, S ^a   Singh, P ^a   Koss, M J ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

AMD; Anti VEGF; Combined therapy; Intrector; Multiple therapy

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; VERTEPORFIN;

ASPIRATION; CANNULA; CLINICAL TRIAL; HUMAN; MONOTHERAPY; PATIENT SAFETY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; SURGICAL INSTRUMENT; VISUAL ACUITY; VITRECTOMY;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58449107399     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027605     Document Type: Review

References (47)

1. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
2. Gragoudas ES, Adamis AP, Cunningham Jr. ET et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816
3. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
4. Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390
5. Chatterjee SP, DaCosta J, Adewoyin T et al. Combined Photodynamic Therapy with Visudyne, Intravitreal Injection of Lucentis and Dexamethasone, and Oral Minocycline in the Treatment of Neovascular Age-Related Macular Degeneration. Ft. Lauderdale: Association of Research in Vision and Ophthalmology -ARVO, 2008
6. Tolentino MJ, Berger A, Misch D et al. Decreased Retreatments and Maintained Efficacy With Triple Therapy (Combination Verteporfin Photodynamic Therapy, Intravitreal Avastin/Lucentis and Intravitreal Dexamethasone Teatments) for Patients with Exudative Age Related Macular Degeneration. Ft. Lauderdale: Association of Research in Vision and Ophthalmology - ARVO, 2008
7. Grossniklaus HE, Ling JX, Wallace TM et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002; 8: 119-126
8. Penfold PL, Liew SC, Madigan MC et al. Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. Invest Ophthalmol Vis Sci 1997; 38: 2125-2133
9. Penfold PL, Madigan MC, Gillies MC et al. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001; 20: 385-414
10. Dvorak HF, Nagy JA, Feng D et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-132
11. Espinosa-Heidmann DG, Reinoso MA, Pina Y et al. Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res 2005; 80: 369-378
12. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496-503
13. Tsutsumi-Miyahara C, Sonoda KH, Egashira K et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br J Ophthalmol 2004; 88: 1217-1222
14. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684
15. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845
16. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480
17. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117: 1329-1345
18. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560
19. Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007; 26: 437-451
20. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143: 510-512
21. D'Amico DJ, Masonson HN, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992-1001 e1006
22. Mieler W. PIER: 1 Year FA/OCT Results in a Study of Ranibizumab (Lucentis®) for Choroidal Neovascularisation (CNV) due to Age related Macular Degeneration (AMD). 24th Annual meeting of the American Society of Retina Specialists and 6th annual meeting of the European Vitreoretinal Society. Cannes, France, 2006
23. Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583
24. Danis RP, Ciulla TA, Pratt LM et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250
25. Gillies MC, Simpson JM, Billson FA et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-340
26. Jonas JB, Akkoyun I, Budde WM et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122: 218-222
27. Lee J, Freeman WR, Azen SP et al. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 2007; 27: 1205-1213
28. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 14-22
29. Ruiz-Moreno JM, Montero JA, Barile S et al. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006; 26: 602-612
30. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-304
31. Tatar O, Adam A, Shinoda K et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006; 142: 95-104
32. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1532-1542
33. Costa RA, Jorge R, Calucci D et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007; 245: 1273-1280
34. Dhalla MS, Shah GK, Blinder KJ et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26: 988-993
35. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114: 1179-1185
36. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140
37. Liggett PE, Colina J, Chaudhry NA et al. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006; 142: 1072-1074
38. Ahmadieh H, Taei R, Soheilian M et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007; 7: 10
39. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
40. Ahmed J, Braun RD, Dunn Jr. R et al. Oxygen distribution in the macaque retina. Invest Ophthalmol Vis Sci 1993; 34: 516-521
41. Holekamp NM, Shui YB, Beebe D. Vitreous consumes oxygen: implications for vitrectomy surgery. Aspen Vitrectomy meeting 2006
42. Stefansson E, Landers 3rd MB. How does vitrectomy affect diabetic macular edema? Am J Ophthalmol 2006; 141: 984-985
43. Stefansson E, Loftsson T. The Stokes-Einstein equation and the physiological effects of vitreous surgery. Acta Ophthalmol Scand 2006; 84: 718-719
44. Saito Y, Lewis JM, Park I et al. Nonvitrectomizing vitreous surgery: a strategy to prevent postoperative nuclear sclerosis. Ophthalmology 1999; 106: 1541-1545
45. Sawa M, Saito Y, Hayashi A et al. Assessment of nuclear sclerosis after nonvitrectomizing vitreous surgery. Am J Ophthalmol 2001; 132: 356-362
46. Holekamp NM. How the Vitreous consumes oxygen. Retina Subspecialty Day of the Annual American Academy of Ophthalmology. New Orleans, 2007
47. Krebs I, Brannath W, Glittenberg C et al. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007; 144: 741-746